HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis.

Abstract
Infantile neuronal ceroid lipofuscinosis (INCL) is an inherited neurodegenerative lysosomal storage disease (LSD) caused by a deficiency in palmitoyl protein thioesterase-1 (PPT1). Studies in Ppt1(-/-) mice demonstrate that glial activation is central to the pathogenesis of INCL. Astrocyte activation precedes neuronal loss, while cytokine upregulation associated with microglial reactivity occurs before and concurrent with neurodegeneration. Therefore, we hypothesized that cytokine cascades associated with neuroinflammation are important therapeutic targets for the treatment of INCL. MW01-2-151SRM (MW151) is a blood-brain barrier penetrant, small-molecule anti-neuroinflammatory that attenuates glial cytokine upregulation in models of neuroinflammation such as traumatic brain injury, Alzheimer's disease, and kainic acid toxicity. Thus, we used MW151, alone and in combination with CNS-directed, AAV-mediated gene therapy, as a possible treatment for INCL. MW151 alone decreased seizure susceptibility. When combined with AAV-mediated gene therapy, treated INCL mice had increased life spans, improved motor performance, and eradication of seizures. Combination-treated INCL mice also had decreased brain atrophy, astrocytosis, and microglial activation, as well as intermediary effects on cytokine upregulation. These data suggest that MW151 can attenuate seizure susceptibility but is most effective when used in conjunction with a therapy that targets the primary genetic defect.
AuthorsShannon L Macauley, Andrew M S Wong, Charles Shyng, David P Augner, Joshua T Dearborn, Yewande Pearse, Marie S Roberts, Stephen C Fowler, Jonathan D Cooper, D Martin Watterson, Mark S Sands
JournalThe Journal of neuroscience : the official journal of the Society for Neuroscience (J Neurosci) Vol. 34 Issue 39 Pg. 13077-82 (Sep 24 2014) ISSN: 1529-2401 [Electronic] United States
PMID25253854 (Publication Type: Journal Article)
CopyrightCopyright © 2014 the authors 0270-6474/14/3413077-06$15.00/0.
Chemical References
  • Anti-Inflammatory Agents
  • Cytokines
  • MW01-2-069A-SRM
  • Pyridazines
  • Pyrimidines
  • Thiolester Hydrolases
  • palmitoyl-protein thioesterase
Topics
  • Animals
  • Anti-Inflammatory Agents (pharmacokinetics, therapeutic use)
  • Blood-Brain Barrier (drug effects, metabolism)
  • Cytokines (genetics, metabolism)
  • Dependovirus (genetics)
  • Genetic Therapy
  • Locomotion
  • Mice
  • Mice, Inbred C57BL
  • Microglia (drug effects, metabolism)
  • Neuronal Ceroid-Lipofuscinoses (therapy)
  • Pyridazines (pharmacokinetics, therapeutic use)
  • Pyrimidines (pharmacokinetics, therapeutic use)
  • Seizures (therapy)
  • Thiolester Hydrolases (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: